May 8th, 2009, by David Pascoe | in the news, tetracyclines
Some very preliminary internet crumbs about a new possible rosacea treatment under development. The treatment under development is listed as a “novel tetracycline”. Warner Chilcott Limited calls itself a “specialty pharmaceutical company, that engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women’s healthcare and dermatology segments primarily in the United States”. In the WCRX 2007 Annual …
December 6th, 2007, by David Pascoe | galderma, oracea, tetracyclines
A recent investor presentation from Collagenex shows some interesting insights into how Collagenex are promoting Oracea. Oracea is promoted as safe and effective for long term use. It was reported that the average duration of Oracea therapy is 4 months, compared to an average of 2.5 months for other rosacea prescriptions. 52% of Oracea prescriptions are refills – the presentation suggests …
September 27th, 2007, by David Pascoe | tetracyclines
Despite promising looking Phase 1 and initial Phase 2 dose finding studies, Incyclinide will no longer be developed as a treatment for rosacea. Incyclinide is a chemically modified tetracycline that its developers – Collagenex, was hoping would become another systemic treatment for rosacea. We did get a warning in May that clinical trials for Incyclinide weren’t all going smoothly – when the …
May 22nd, 2007, by David Pascoe | tetracyclines
Collagenex has announced that their ongoing trials to find the best dosage for Incyclinide have discovered that 40mg can cause photo-toxicity.
Collagenex is conducting parallel Phase II trials for Incyclinide for both acne and rosacea.
As detailed in a recent news item, incyclinide targets conditions other than rosacea, Incyclinide differs from a non-antibiotic tetracycline in that it is also chemically modified. Thus we might expect that …
April 24th, 2007, by David Pascoe | tetracyclines
There has been a lot of publicity lately about Oracea, which is a low dosage, sustained release 40mg form of doxycyline. Oracea was born out of the expiration of the patent on periostat – a twice a day 20mg dose of doxycycline originally targetted at gum disease. Another new low dose antiobiotic is Solodyn (45mg, 90mg and 135mg of extended release minocycline HCL, dose …
|
|
|
|
|
|
|
|
 |